This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Jan 5:340:b5493.

doi: 10.1136/bmj.b5493.

NICE and new: appraising innovation

Robin E Ferner¹, Dyfrig A Hughes, Jeffrey K Aronson

Affiliations

PMID: 20051468
DOI: 10.1136/bmj.b5493

NICE and new: appraising innovation

Robin E Ferner et al. BMJ. 2010.

. 2010 Jan 5:340:b5493.

doi: 10.1136/bmj.b5493.

Authors

Robin E Ferner¹, Dyfrig A Hughes, Jeffrey K Aronson

Affiliation

¹ West Midlands Centre For Adverse Drug Reactions, City Hospital, Birmingham B18 7QH.

PMID: 20051468
DOI: 10.1136/bmj.b5493

No abstract available

PubMed Disclaimer

Similar articles

Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA, Hill SR, Harris A. Henry DA, et al. JAMA. 2005 Nov 23;294(20):2630-2. doi: 10.1001/jama.294.20.2630. JAMA. 2005. PMID: 16304078 No abstract available.
Quality, innovation, and value for money: NICE and the British National Health Service.
Pearson SD, Rawlins MD. Pearson SD, et al. JAMA. 2005 Nov 23;294(20):2618-22. doi: 10.1001/jama.294.20.2618. JAMA. 2005. PMID: 16304076
Considering the value associated with innovation in health technology appraisal decisions (deliberations): a NICE thing to do?
Green C. Green C. Appl Health Econ Health Policy. 2010;8(1):1-5. doi: 10.1007/BF03256161. Appl Health Econ Health Policy. 2010. PMID: 20038189 No abstract available.
Economic evaluation: an introduction.
Raftery J. Raftery J. BMJ. 1998 Mar 28;316(7136):1013-4. doi: 10.1136/bmj.316.7136.1013. BMJ. 1998. PMID: 9550969 Free PMC article. Review. No abstract available.
Health Technology Assessment in the UK.
Raftery J, Powell J. Raftery J, et al. Lancet. 2013 Oct 12;382(9900):1278-85. doi: 10.1016/S0140-6736(13)61724-9. Lancet. 2013. PMID: 24120204 Review.

See all similar articles

Cited by

Value-based pricing: incentive for innovation or zero net benefit?
Hughes DA. Hughes DA. Pharmacoeconomics. 2011 Sep;29(9):731-5. doi: 10.2165/11592570-000000000-00000. Pharmacoeconomics. 2011. PMID: 21736392 No abstract available.
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
Towse A. Towse A. Br J Clin Pharmacol. 2010 Sep;70(3):360-6. doi: 10.1111/j.1365-2125.2010.03740.x. Br J Clin Pharmacol. 2010. PMID: 20716236 Free PMC article.
Pharmacoeconomics.
Hughes DA. Hughes DA. Br J Clin Pharmacol. 2012 Jun;73(6):968-72. doi: 10.1111/j.1365-2125.2012.04247.x. Br J Clin Pharmacol. 2012. PMID: 22360714 Free PMC article.
Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI).
[No authors listed] [No authors listed] J Prev Med Hyg. 2019 Oct 15;60(3 Suppl 1):E1-E384. doi: 10.15167/2421-4248/jpmh2019.60.3s1. eCollection 2019 Oct. J Prev Med Hyg. 2019. PMID: 31777763 Free PMC article. No abstract available.
Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.
Linley WG, Hughes DA. Linley WG, et al. Pharmacoeconomics. 2012 Sep 1;30(9):779-94. doi: 10.2165/11591530-000000000-00000. Pharmacoeconomics. 2012. PMID: 22676385

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.